| Nov 17 |
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 15 |
Vivos Therapeutics GAAP EPS of -$0.40, revenue of $3.86M
|
| Nov 15 |
Vivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
|
| Nov 15 |
Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 13 |
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
|
| Oct 8 |
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
|
| Sep 19 |
Vivos Therapeutics announces $4.3M registered direct offering of common stock
|
| Sep 19 |
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
|
